iBio Medical shareholder Mao Liping plans to reduce holdings of no more than 1.934 million shares through block trading, accounting for 1% of total share capital

Log in to Sina Finance App and search for [Disclosure of Information] to see more evaluation levels

On March 19, 2026, Aibono (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as “Aibono Medical”) announced a shareholder share reduction plan. The company’s shareholder, Mr. Mao Liping, intends to reduce his holdings through block trades, with a maximum of 1.934 million shares, accounting for 1% of the total share capital.

Shareholder and Concerted Action Partner Information

The announcement shows that as of the disclosure date, Mr. Mao Liping holds 5,604,413 shares of Aibono Medical, representing 2.90% of the total share capital. Together with his concerted action partner, Ms. Bai Ying, they hold a total of 11,304,459 shares, accounting for 5.85%. The shares held by Mao Liping were acquired before the company’s IPO and through capital reserve dividends after listing, with these shares listed and tradable on July 31, 2023, and June 5, 2024, respectively.

Details of the Reduction Plan

According to the announcement, the main points of Mao Liping’s reduction plan are as follows:

• Reduction Quantity: No more than 1,934,000 shares, or no more than 1% of the company’s total share capital;
• Reduction Method: Implemented through block trades;
• Reduction Period: Within three months after 15 trading days from the date of the announcement, i.e., from April 10, 2026, to July 9, 2026;
• Reduction Price: Determined based on the market price at the time of implementation. If the company distributes dividends, bonus shares, or other capital adjustments during this period, the plan will be adjusted accordingly.

Historical Reduction Records

The announcement also discloses that Ms. Bai Ying, Mr. Mao Liping’s concerted action partner, has a record of reductions in the past 12 months. Between July 22, 2025, and September 3, 2025, Bai Ying reduced 3,862,700 shares, accounting for 1.9972% of the total share capital, at a price range of 65.72-74.64 yuan per share. This reduction plan was pre-disclosed on June 4, 2025.

Reasons for Reduction and Commitment Fulfillment

The reason for Mao Liping’s reduction is “personal funding needs.” The announcement emphasizes that this reduction plan complies with his previous commitments regarding share lock-up and reduction. According to the commitments, shares held before the IPO will not be transferred within 36 months after the company’s listing. After the lock-up period, reductions within two years will not be below the company’s initial offering price (adjusted for rights and dividends), and he will fulfill information disclosure obligations before the reduction. This reduction is consistent with previously disclosed commitments.

Risk Reminder

Aibono Medical notes in the announcement that the implementation of this reduction plan is uncertain. Mao Liping will decide whether to implement and the specific reduction quantity and price based on market conditions, the company’s stock price, and other factors. The company states that this reduction will not significantly impact corporate governance or ongoing operations and will strictly comply with relevant laws and regulations, timely fulfill information disclosure obligations, and investors are advised to invest rationally and be aware of risks.

Disclaimer: The market carries risks; investment should be cautious. This article is automatically published by an AI model based on third-party databases and does not represent Sina Finance’s views. Any information in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for accuracy. If you have questions, contact biz@staff.sina.com.cn.

Click here to view the original announcement>>